PLYMOUTH, Minn.--(BUSINESS WIRE)--PlaCor, Inc. announced today that John Reinke has been appointed Chief Executive Officer, effective September 4, 2007. William S. Haworth has been named Chief Technology Officer and will focus on the continued development of the Company’s platelet reactivity testing technology.
Mr. Reinke was most recently a Senior Vice President for UnitedHealth Group in Minnetonka, Minnesota, responsible for leading innovation initiatives for service, operations, technology and new products. He is a leading expert in consumer-directed health (CDH) and helped United become a market leader in this arena by supporting new service models, new technologies and due diligence for related acquisitions, including the purchase of Definity Health. Mr. Reinke has 30 years of experience in health care, management consulting and financial services and has held positions in operations, sales and marketing, product development and finance.
PlaCor, Inc., based in Plymouth, Minnesota, is a privately-held corporation which is developing a simple, easy to use, proprietary, global, point-of-care test to measure platelet reactivity. Anti-platelet drugs, such as aspirin and Plavix®, are often prescribed by physicians to inhibit platelet reactivity as part of a regimen to reduce the occurrence and severity of heart attacks and strokes. The PlaCor test will be used initially to monitor anti-platelet therapy. The test is available for research purposes only and is currently the subject of a premarket notification review by the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
Contact: PlaCor, Inc. Joseph Margarit, 763-398-6216 joem@placorinc.com
Source: PlaCor, Inc.
